COMP <GO>
ACAD vs UNH // OPTIONS IMPLIED MOVE & PUT/CALL SKEW
ACADIA Pharmaceuticals Inc. (NASDAQ) VS. UnitedHealth Group Incorporated (NYSE) • 15-METRIC TALLY: ACAD 6
— UNH 6
■ METRIC PARITY
LAST: $20.76 (+2.17%) • MKT CAP: $3.58B
options-implied-move
—
LAST: $410.91 (+0.94%) • MKT CAP: $368.83B
options-implied-move
6.74%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ACAD VS. UNH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ACAD | UNH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 91.70% | 88.57% | +3.13 | ACAD | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 7.90% | 11.47% | -3.57 | UNH | /roic <GO> |
| EV/EBITDA & P/E Valuation | 31.2x | 16.4x | +14.75 | UNH | /valuation <GO> |
| Free Cash Flow Yield | 2.94% | 6.48% | -3.54 | UNH | /fcf-yield <GO> |
| Operating Margin | 9.80% | 4.82% | +4.98 | ACAD | /operating-margins <GO> |
| Net Profit Margin | 36.50% | 3.14% | +33.36 | ACAD | /net-margins <GO> |
| Revenue Growth (YoY) | 11.90% | 6.46% | +5.44 | ACAD | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.28% | -2.28 | UNH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 6.26 | 3.12 | +3.14 | ACAD | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 7/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew ACTIVE | — | 6.74% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 45.5 | 59.2 | -13.68 | UNH | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.33 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 8.5x | 17.1x | -8.59 | ACAD | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $3.58B | $368.83B | -$365.25B | UNH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ACAD REV | UNH REV | ACAD GROSS % | UNH GROSS % | ACAD FCF | UNH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $1.07B | $447.57B | 91.7% | 88.7% | $105.1M | $16.07B |
| FY 2024 | $957.8M | $400.28B | 91.5% | 88.3% | $157.2M | $20.70B |
| FY 2023 | $726.4M | $371.62B | — | 89.6% | $16.7M | $25.68B |
| FY 2022 | — | $324.16B | — | 89.6% | — | $23.40B |
| FY 2021 | — | $287.60B | — | 89.2% | — | $19.89B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ACAD // BETA —
UNH // BETA 0.33